MedVellum
MedVellum
Back to Library

ARDS (Acute Respiratory Distress Syndrome)

On This Page

Overview

ARDS (Acute Respiratory Distress Syndrome)

Quick Reference

Critical Alerts

  • ARDS mortality remains 30-40% even with optimal management
  • Lung protective ventilation is the cornerstone of treatment
  • Low tidal volume (6 mL/kg IBW) reduces mortality - this is non-negotiable
  • Prone positioning for 16+ hours improves survival in moderate-severe ARDS
  • Identify and treat the underlying cause - ARDS is a syndrome, not a diagnosis

Key Diagnostics

  • Berlin Criteria for diagnosis
  • P/F ratio (PaO2/FiO2) on PEEP ≥5 cmH2O
  • Chest X-ray or CT (bilateral opacities)
  • Echocardiogram (exclude cardiogenic edema)
  • Labs to identify underlying cause

Emergency Treatments

  • Intubation and mechanical ventilation with lung protective settings
  • Tidal volume 6 mL/kg ideal body weight (calculate IBW!)
  • Plateau pressure ≤30 cmH2O
  • PEEP titration (use PEEP/FiO2 table or driving pressure)
  • Prone positioning for P/F <150 (16+ hours/day)
  • Conservative fluid strategy after initial resuscitation

Definition

Acute Respiratory Distress Syndrome (ARDS) is a form of acute, diffuse, inflammatory lung injury leading to increased pulmonary vascular permeability, increased lung weight, and loss of aerated lung tissue. It is characterized by acute onset of hypoxemia and bilateral pulmonary infiltrates not fully explained by cardiac failure.

Berlin Definition (2012)

CriterionDefinition
TimingWithin 1 week of known clinical insult or new/worsening respiratory symptoms
ImagingBilateral opacities not fully explained by effusions, lobar/lung collapse, or nodules
Origin of edemaRespiratory failure not fully explained by cardiac failure or fluid overload (need objective assessment if no risk factor)
OxygenationP/F ratio with PEEP ≥5 cmH2O

Severity Classification

SeverityP/F RatioMortality
Mild201-30027%
Moderate101-20032%
Severe≤10045%

Epidemiology

  • Incidence: 10-80 per 100,000 person-years
  • ICU frequency: 10-15% of ICU admissions; 23% of mechanically ventilated patients
  • Mortality: 30-40% overall; higher in severe ARDS
  • Long-term: Survivors often have persistent functional limitations

Pathophysiology

Phases of ARDS

Exudative Phase (Days 1-7)

  • Diffuse alveolar damage
  • Hyaline membrane formation
  • Epithelial and endothelial injury
  • Protein-rich edema fills alveoli
  • Inflammatory cell infiltration
  • Surfactant dysfunction

Proliferative Phase (Days 7-21)

  • Type II pneumocyte proliferation
  • Fibroblast proliferation
  • Early fibrosis
  • Some resolution begins

Fibrotic Phase (>3 weeks)

  • Extensive fibrosis (in some patients)
  • Permanent lung architecture changes
  • May not occur if early recovery

Lung Mechanics in ARDS

Baby Lung Concept

  • Not all lung is damaged equally
  • Aerated lung volume is reduced ("baby lung")
  • Standard tidal volumes overdistend remaining functional lung
  • Regional heterogeneity leads to injury from mechanical ventilation

Mechanisms of Ventilator-Induced Lung Injury (VILI)

TypeMechanism
VolutraumaOverdistension from high tidal volumes
BarotraumaHigh airway pressures
AtelectraumaRepeated opening/closing of collapsed alveoli
BiotraumaInflammatory mediator release from mechanical stress

Underlying Causes

Pulmonary (Direct)

CauseFrequency
PneumoniaMost common
AspirationCommon
Pulmonary contusionTrauma
Inhalation injuryBurns, chemicals
Near-drowningAspiration

Extrapulmonary (Indirect)

CauseFrequency
SepsisMost common overall
PancreatitisCommon
Massive transfusionTRALI
Trauma/burnsSystemic inflammation
Drug overdoseVarious mechanisms

Clinical Presentation

Symptoms and Signs

Symptoms

Physical Examination

FindingSignificance
TachypneaOften severe (RR 30-50)
TachycardiaResponse to hypoxemia
HypoxemiaDespite supplemental oxygen
Accessory muscle useIncreased work of breathing
CyanosisSevere hypoxemia
CracklesBilateral, diffuse
Decreased breath soundsConsolidation

Imaging Findings

Chest X-ray

CT Chest

FindingDescription
Ground-glass opacitiesAlveolar filling
ConsolidationComplete alveolar filling
Dependent consolidationGravitational distribution
Anterior "baby lung"Preserved aerated lung
Air bronchogramsWithin consolidated lung

Laboratory Findings


Dyspnea (progressive, often rapid onset)
Common presentation.
Cough
Common presentation.
Chest discomfort
Common presentation.
Anxiety, restlessness
Common presentation.
Red Flags (Life-Threatening)

Critical Findings

Red FlagConcernAction
P/F ratio <100 despite high FiO2Severe ARDSProne positioning, consider ECMO referral
Refractory hypoxemiaFailing conventional therapyECMO evaluation
Plateau pressure >0 cmH2OLung overdistensionReduce Vt, accept permissive hypercapnia
pH <7.15 with hypercapniaSevere respiratory acidosisMay need to increase Vt slightly
Hemodynamic instabilityARDS + shockCareful fluid management, pressors
New pneumothoraxBarotraumaChest tube, reduce PEEP/Vt

Poor Prognostic Indicators

  • Age >65 years
  • Pre-existing organ dysfunction
  • Higher APACHE II/III scores
  • Failure to improve P/F ratio by day 7
  • Underlying cause (sepsis > trauma)
  • Immunocompromised status

Differential Diagnosis

Conditions Mimicking ARDS

ConditionKey Features
Cardiogenic pulmonary edemaElevated BNP, responds to diuretics, echo findings
Bilateral pneumoniaMay meet ARDS criteria - treat underlying cause
Pulmonary hemorrhageDiffuse alveolar hemorrhage, hemoptysis, dropping Hb
Acute eosinophilic pneumoniaEosinophilia on BAL, responds to steroids
Cryptogenic organizing pneumoniaSubacute onset, responds to steroids
Pulmonary embolismMay have bilateral infiltrates; CT-PA shows PE
Lymphangitic carcinomatosisCancer history, more gradual onset

Distinguishing ARDS from Cardiogenic Pulmonary Edema

FeatureARDSCardiogenic Edema
BNPNormal or mildly elevatedMarkedly elevated (>00)
EchocardiogramNormal LV functionReduced EF, elevated filling pressures
Response to diureticsMinimalSignificant improvement
Protein in edema fluidHigh (exudate)Low (transudate)
PCWP (if measured)≤18 mmHg>8 mmHg

Diagnostic Approach

Establishing Diagnosis

Step 1: Clinical Assessment

  • Identify acute respiratory symptoms (<1 week)
  • Known or suspected trigger (infection, aspiration, etc.)
  • Progressive hypoxemia despite oxygen

Step 2: Oxygenation Assessment

Calculate P/F Ratio:
P/F = PaO2 (from ABG) ÷ FiO2 (as decimal)

Example: PaO2 60 mmHg on FiO2 0.60 → P/F = 100

Must be on PEEP ≥5 cmH2O for Berlin criteria

Step 3: Imaging

  • Chest X-ray showing bilateral opacities
  • Not fully explained by effusion, atelectasis, nodules

Step 4: Exclude Cardiogenic Cause

  • Echocardiogram to assess LV function
  • BNP/NT-proBNP
  • Clinical context (no history of heart failure, volume overload)

Identify Underlying Cause

WorkupPurpose
Blood culturesSepsis
ProcalcitoninBacterial infection
Respiratory viral panelViral pneumonia
Urine Legionella/PneumococcalAtypical pneumonia
BAL if indicatedIdentify pathogen, hemorrhage, eosinophils
LipasePancreatitis
Drug/toxicology screenDrug-induced ARDS

Treatment

Lung Protective Ventilation (ESSENTIAL)

ARDSNet Protocol

ParameterTarget
Tidal Volume6 mL/kg ideal body weight (IBW)
Plateau Pressure≤30 cmH2O
PEEPTitrate per PEEP/FiO2 table
RR14-35 to maintain pH goal
FiO2Lowest to achieve SpO2 88-95%
pH goal7.30-7.45

Calculate Ideal Body Weight

Males: IBW (kg) = 50 + 2.3 × (height in inches - 60)
Females: IBW (kg) = 45.5 + 2.3 × (height in inches - 60)

Example: 5'10" male = 50 + 2.3 × (70-60) = 73 kg
Tidal volume = 73 × 6 = 438 mL (round to 440 mL)

PEEP/FiO2 Table (Lower PEEP/Higher FiO2)

FiO20.30.40.50.60.70.80.91.0
PEEP55-88-101010-141414-1818-24

Prone Positioning

Indications

  • P/F ratio <150 despite optimized ventilation
  • Within 36 hours of ARDS diagnosis

Protocol

Duration: ≥16 hours per day (ideally 16-20 hours)
Positioning: Carefully with team (prevent lines/tube issues)
Continue: Until P/F &gt;150 on FiO2 ≤0.6 and PEEP ≤10

Benefits:
- Mortality reduction in severe ARDS (PROSEVA trial: NNT = 6)
- Improved V/Q matching
- Better lung recruitment
- Reduced VILI

Neuromuscular Blockade

Consider Early (First 48 Hours) If:

  • Severe ARDS (P/F <150)
  • Ventilator dyssynchrony
  • Adjunct to prone positioning

Agent: Cisatracurium 15 mg bolus, then 37.5 mg/hr infusion

Evidence: ACURASYS trial showed mortality benefit; ROSE trial did not confirm. Use selectively.

Fluid Management

Conservative Fluid Strategy

  • After initial resuscitation for shock
  • Target CVP <4 or PAOP <8
  • Diuretics to achieve net negative balance
  • FACTT trial: Fewer ventilator days with conservative strategy

Recruit and Retain

Recruitment Maneuvers

  • Transient increase in PEEP (30-40 cmH2O for 30-40 seconds)
  • Evidence mixed; use with caution
  • Monitor for barotrauma, hypotension

Corticosteroids

Current Evidence

  • Dexamethasone 20mg × 5 days, then 10mg × 5 days (DEXA-ARDS trial)
  • Started early in moderate-severe ARDS
  • Reduces duration of mechanical ventilation and may reduce mortality
  • Avoid in uncontrolled infection

ECMO (Extracorporeal Membrane Oxygenation)

Consider If:

  • P/F <80 for >6 hours despite optimization
  • P/F <50 for >3 hours
  • pH <7.25 with PaCO2 >60 for >6 hours
  • Murray score ≥3

Contraindications

  • Mechanical ventilation >7 days
  • Major contraindication to anticoagulation
  • Poor baseline functional status

Disposition

ICU Admission

  • All patients with ARDS require ICU admission
  • Invasive mechanical ventilation required in majority
  • Continuous monitoring essential
  • Prone positioning requires experienced team

Considerations for Transfer

Transfer to ARDS/ECMO Center If:

  • Refractory hypoxemia despite optimal management
  • ECMO may be indicated
  • Lack of expertise in lung protective ventilation or proning

Prognosis Discussions

  • Prepare family for prolonged ICU course
  • Mortality 30-40% (higher in severe)
  • Survivors may have long-term disability
  • Goals of care discussions early

Patient Education (For Families)

Understanding ARDS

  • ARDS is severe lung inflammation causing very low oxygen levels
  • It requires a breathing machine (ventilator) to support breathing
  • Treatment focuses on allowing lungs to heal while preventing further damage
  • Recovery takes weeks to months

What to Expect

  • Patient will be sedated and on ventilator
  • May need to lie on stomach (prone position) to help oxygen
  • Multiple lines and monitors
  • Daily updates from ICU team
  • Prolonged ICU and hospital stay likely

Questions Families Should Ask

  • What caused the ARDS?
  • How severe is it (P/F ratio category)?
  • What treatments are being used?
  • Are there signs of improvement?
  • What are the potential complications?

Special Populations

COVID-19 ARDS

Differences from Classic ARDS

  • May have preserved lung compliance initially ("L-type")
  • High thrombotic risk
  • Prolonged course
  • Dexamethasone proven beneficial (RECOVERY trial)

Management Modifications

  • Awake proning if not intubated
  • Anticoagulation (at least prophylactic, some use therapeutic)
  • Tocilizumab/baricitinib in select patients
  • Avoid delayed intubation

Immunocompromised Patients

  • Higher mortality
  • Consider atypical pathogens (PCP, CMV, Aspergillus)
  • Bronchoscopy with BAL may be needed
  • Empiric coverage may need to be broader

Pregnancy

  • Prone positioning can be done with appropriate support
  • ECMO used in severe refractory cases
  • Delivery decisions based on gestational age and maternal status
  • Multi-disciplinary approach essential

Trauma

  • Pulmonary contusion may progress to ARDS
  • Hemorrhage complicates fluid management
  • Fat embolism syndrome in long bone fractures
  • Aggressive pain control to prevent splinting

Quality Metrics

Performance Indicators

MetricTarget
Lung protective ventilation (Vt ≤6 mL/kg IBW)100%
Plateau pressure ≤30 cmH2O100%
IBW calculated and documented100%
Prone positioning if P/F <150>0%
Daily spontaneous breathing trial when appropriate100%
DVT prophylaxis100%

Documentation Requirements

  • P/F ratio with calculation
  • IBW calculation
  • Ventilator settings with rationale
  • Response to interventions
  • Underlying cause identified or workup ongoing
  • Family discussions documented

Key Clinical Pearls

Diagnostic Pearls

  1. Always calculate P/F ratio - defines severity and guides treatment
  2. Bilateral infiltrates alone are not ARDS - need acute onset and hypoxemia
  3. Echo to exclude cardiogenic edema - especially if no clear ARDS trigger
  4. Find the underlying cause - ARDS is a syndrome, not a diagnosis
  5. P/F ratio requires PEEP ≥5 for Berlin criteria

Treatment Pearls

  1. 6 mL/kg IBW is non-negotiable - this saves lives
  2. Calculate IBW using height, NOT actual weight
  3. Prone early if P/F <150 - mortality benefit proven
  4. Accept permissive hypercapnia (pH >7.20) to maintain low Vt
  5. Conservative fluids after initial resuscitation

Disposition Pearls

  1. All ARDS goes to ICU - no exceptions
  2. Consider ECMO center transfer early - before patient is too sick to transport
  3. Prolonged course expected - prepare family
  4. Survivors need rehabilitation - functional impairment common
  5. Goals of care discussions should happen early

References
  1. ARDS Definition Task Force. Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012;307(23):2526-2533.
  2. Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes for acute lung injury and ARDS. N Engl J Med. 2000;342(18):1301-1308.
  3. Guérin C, et al. Prone positioning in severe acute respiratory distress syndrome (PROSEVA). N Engl J Med. 2013;368(23):2159-2168.
  4. Papazian L, et al. Neuromuscular blockers in early acute respiratory distress syndrome (ACURASYS). N Engl J Med. 2010;363(12):1107-1116.
  5. Villar J, et al. Dexamethasone treatment for the acute respiratory distress syndrome (DEXA-ARDS): a multicentre, randomised controlled trial. Lancet Respir Med. 2020;8(3):267-276.
  6. Fan E, et al. An Official American Thoracic Society/European Society of Intensive Care Medicine/Society of Critical Care Medicine Clinical Practice Guideline: Mechanical Ventilation in Adult Patients with Acute Respiratory Distress Syndrome. Am J Respir Crit Care Med. 2017;195(9):1253-1263.

Version History
VersionDateChanges
1.02025-01-15Initial comprehensive version with 14-section template

At a Glance

EvidenceStandard
Last UpdatedRecently

Guidelines

  • NICE Guidelines
  • BTS Guidelines
  • RCUK Guidelines